273 related articles for article (PubMed ID: 29423787)
21. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients.
Feinstein MJ; Achenbach CJ; Stone NJ; Lloyd-Jones DM
Am J Cardiol; 2015 Jun; 115(12):1760-6. PubMed ID: 25907504
[TBL] [Abstract][Full Text] [Related]
23. Dyslipidemia and lipid management in HIV-infected patients.
Lo J
Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):144-7. PubMed ID: 21297466
[TBL] [Abstract][Full Text] [Related]
24. HIV infection and lipids.
Jain A; Kolvekar T; Nair DR
Curr Opin Cardiol; 2018 Jul; 33(4):429-435. PubMed ID: 29601329
[TBL] [Abstract][Full Text] [Related]
25. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
Troll JG
Curr Atheroscler Rep; 2011 Feb; 13(1):51-6. PubMed ID: 21181310
[TBL] [Abstract][Full Text] [Related]
26. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Ciaffi L; Cavassini M; Genne D; Delhumeau C; Spycher Elbes R; Hill A; Wandeler G; Fehr J; Stoeckle M; Schmid P; Hirschel B; Montecucco F; Calmy A;
Eur J Clin Invest; 2015 Jul; 45(7):720-30. PubMed ID: 25989829
[TBL] [Abstract][Full Text] [Related]
27. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration.
Manfredi R; Calza L; Chiodo F
J Biol Regul Homeost Agents; 2006; 20(1-2):1-9. PubMed ID: 18088548
[TBL] [Abstract][Full Text] [Related]
28. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin: a review of its use in the management of dyslipidemia.
Scott LJ; Curran MP; Figgitt DP
Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P; Guidi M; Alves Saldanha S; Stader F; Traytel A; Cavassini M; Stoeckle M; Buclin T; Marzolini C; Decosterd LA; Csajka C;
Clin Pharmacokinet; 2021 Mar; 60(3):379-390. PubMed ID: 33124006
[TBL] [Abstract][Full Text] [Related]
32. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
[TBL] [Abstract][Full Text] [Related]
34. No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy.
Calza L; Colangeli V; Magistrelli E; Manfredi R; Bon I; Re MC; Viale P
HIV Med; 2016 Sep; 17(8):631-3. PubMed ID: 27028348
[TBL] [Abstract][Full Text] [Related]
35. Effect of statin on arginine metabolites in treated HIV-infection.
Dirajlal-Fargo S; El Kamari V; Sattar A; Alam K; Funderburg N; Labbato D; Pirro L; Longenecker CT; Wilson WH; McComsey GA
Atherosclerosis; 2017 Nov; 266():74-80. PubMed ID: 28992467
[TBL] [Abstract][Full Text] [Related]
36. Statins to improve cardiovascular outcomes in treated HIV infection.
Longenecker CT; Eckard AR; McComsey GA
Curr Opin Infect Dis; 2016 Feb; 29(1):1-9. PubMed ID: 26658651
[TBL] [Abstract][Full Text] [Related]
37. Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy.
Calza L; Colangeli V; Magistrelli E; Contadini I; Bon I; Re MC; Conti M; Mancini R; Viale P
AIDS Res Hum Retroviruses; 2017 Feb; 33(2):126-132. PubMed ID: 27618139
[TBL] [Abstract][Full Text] [Related]
38. Devolving of statin prescribing to general practitioners for HIV-infected patients receiving antiretroviral therapy.
Benn PD; Miller RF; Evans L; Minton J; Edwards SG
Int J STD AIDS; 2009 Mar; 20(3):202-4. PubMed ID: 19255272
[TBL] [Abstract][Full Text] [Related]
39. Room for manoeuvre when prescribing statins to dyslipidaemic patients on antiretroviral therapy.
Myers J; Rayment M; Sonecha S; Moyle G; Boffito M
HIV Med; 2012 Mar; 13(3):190-2. PubMed ID: 22296166
[No Abstract] [Full Text] [Related]
40. Safety of statin therapy in HIV/hepatitis C virus-coinfected patients.
Milazzo L; Menzaghi B; Corvasce S; Bonfanti P; Rusconi S; Ridolfo AL; Antinori S
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):258-60. PubMed ID: 17895771
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
